Today: 20 May 2026
Browse Category

NASDAQ:ZBIO 22 December 2025 - 6 January 2026

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.
6 January 2026
··
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma shares were unchanged at $39.05 in premarket trading Tuesday after falling 8.1% Monday. The stock is down about 12% from its December 24 high as investors await Phase 3 INDIGO trial results expected around year-end. Monday’s session saw shares dip to $38.96 before closing at $39.05. Technical support is near $37.78, with resistance just above $41.
30 December 2025
·
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma shares jumped about 14% to $41.23 on December 22, 2025, hitting a record high of $41.67 ahead of expected Phase 3 INDIGO trial results for obexelimab in IgG4-related disease. Citi and Wedbush both reiterated bullish ratings and price targets, citing the upcoming clinical data as a near-term catalyst.
22 December 2025
·

Stock Market Today

  • Trump's Truth Social Withdraws Bitcoin and Bitcoin-Ethereum ETF Applications Amid Market Pressure
    May 20, 2026, 7:22 AM EDT. Trump Media & Technology Group has withdrawn its applications for Bitcoin and Bitcoin-Ethereum exchange-traded funds (ETFs), citing a strategic shift to pursue a different regulatory framework under the Investment Company Act of 1940 ('40 Act) instead of the Securities Act of 1933 ('33 Act). Yorkville America, the investment advisor, highlighted that the '40 Act allows more flexible investment strategies. This move comes amid intense fee competition in the U.S. spot Bitcoin ETF market, valued at $57.4 billion since January 2024, following Morgan Stanley's MSBT launch, which offers a low 0.14% expense ratio. The withdrawal underscores heightened competition and evolving regulatory approaches in the crypto ETF space.

Latest articles

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

20 May 2026
InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

20 May 2026
Micware shares jumped 97.7% to $9.33 in premarket U.S. trading Wednesday, rebounding above last week’s $8 IPO price after closing Tuesday at $4.72. A new SEC filing showed Toyota owns 11.6% of Micware’s ordinary shares. The Japanese automotive software firm raised $22.8 million in its Nasdaq debut last week.
Dow edges up while Nasdaq falls as bond worries drag on

Futures Edge Higher Ahead of Nvidia Earnings as Wall Street Watches Key Report

20 May 2026
Nasdaq 100 futures rose 0.73% and S&P 500 futures gained 0.35% ahead of Wednesday’s open, with Nvidia set to report earnings after the close. Options markets priced in a 6.5% swing for Nvidia, equal to about $355 billion in market value. In premarket trading, Nvidia shares rose 1.84%, while Micron, Intel, and AMD also advanced. Fed minutes are due at 2:00 p.m. EDT.
Go toTop